Grand Rounds February 23, 2024: Virtual Vigilance: Monitoring of Decentralized Clinical Trials (Adrian Hernandez, MD; Christopher J. Lindsell, PhD)
Rethinking Clinical Trials
FEBRUARY 28, 2024
In a remote study, it would be possible for duplicate enrollment, falsified or fabricated eligibility source documents, or data completed by surrogates. Under RBM, the process by which study materials get to participants should be considered high risk and monitored accordingly. Were there any major GCP-related issues? I think we must.
Let's personalize your content